The burgeoning landscape of therapy for weight management and type 2 diabetes is currently witnessing considerable excitement surrounding both retatrutide and tirzepatide. While both represent novel dual GIP and GLP-1 target agonists, significant differences in their pharmacological profiles and clinical investigation results are emerging. Retatrut

Arriving in the landscape of excess body fat therapy, retatrutide presents a unique approach. Unlike many current medications, retatrutide operates as a dual agonist, simultaneously targeting both glucagon-like peptide-1 (GLP-1) and glucose-responsive insulinotropic substance (GIP) binding sites. This concurrent engagement promotes various advantag